Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant acellular pertussis vaccine
- Development stage
- Unknown
- Lead developer
- Yonsei University
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The **recombinant acellular pertussis vaccine** is an immunization designed to prevent pertussis (whooping cough), composed of antigens produced via recombinant DNA technology rather than purified directly from Bordetella pertussis. The main antigens are genetically detoxified pertussis toxin (PT), filamentous hemagglutinin (FHA), and pertactin (PRN), often expressed and purified from recombinant hosts such as E. coli. This vaccine induces humoral and cellular immunity, including robust CD4+ T cell responses in lung tissue and strong antibody responses for FHA and PRN. Recombinant vaccines may yield higher or more sustained immunogenicity compared to traditional chemically inactivated acellular pertussis vaccines. They are intended for booster use in adolescents/adults, and may be formulated alone or in combination with diphtheria and tetanus toxoids[1][3]. Developers in Korea include Yonsei University and Vaccine Innovative Technology ALliance; GC Pharma incorporates recombinant antigens in trivalent DTaP platforms. The mechanism of action is to induce neutralizing antibodies and cellular immunity against pertussis toxin to prevent infection.
- Other names
- recombinant aPraPrecombinant pertussis vaccine
02
Targets
FHA (Filamentous hemagglutinin)PT (Pertussis toxin)PRN (Pertactin)
Beyond the preview
Go deeper on recombinant acellular pertussis vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant acellular pertussis vaccine.